LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC [MA08.04]

Authors :: Riudavets, M.
Mezquita, L.
Auclin, E.
Benitez, J.C.
Le Pechoux, C.
Majem, M.
Dempsey, N.
Lobefaro, R.
Nadal, E.
Amores, A.
Menis, J.
Tagliamento, M.
López-Castro, R.
Ponce, S.
Bosch-Barrera, J.
Aboubakar Nana, Frank
Mosquera, J.
Pilotto, S.
Reyes, R.
Mielgo, X.
Duchemann, B.
Mosteiro, M.
Mussat, E.
De Giglio, A.
Scheffler, M.
Campayo, M.
Botticella, A.
Naltet, C.
Lavaud, P.
Lopes, G.
Signorelli, D.
Garcia-Campelo, R.
Besse, B.
Planchard, D.
2020 World Conference on Lung Cancer
UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie
UCL - (SLuc) Service de pneumologie
Source :: Journal of Thoracic Oncology, Vol. 16, no.3, p. S161 (2021)
Publication Year :: 2021
Publisher :: Elsevier, 2021.
Abstract: INTRODUCTION : The lung immune prognostic index (LIPI), which combines pretreatment derived neutrophils/[leukocytes minus neutrophils] ratio (dNLR) >3 and lactate dehydrogenase (LDH) > upper limit of normal (ULN), is associated with outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICI). We aimed to assess whether pretreatment LIPI correlates with durvalumab efficacy after concurrent chemoradiotherapy in the locally advanced setting.

Tools